Publications scientifiques sur le VIH
Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study [abstract].
2011
Khanlou H, Gathe J, Schrader S, et al.
Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2011; Chicago, Illinois, USA.
Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study.
2011
Khanlou H, Gathe J, Schrader S, et al.
Oral presentation at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2011; Chicago, Illinois, USA.
Durable efficacy and continued safety of ibalizumab in treatment-experienced patients [abstract].
2011
Khanlou H, Devente J, Fessel J, et al.
The Annual Meeting of the Infectious Diseases Society of America (IDSA); October 20-23, 2011; Boston, Massachusetts, USA.
Durable efficacy and continued safety of ibalizumab in treatment-experienced patients.
2011
Khanlou H, Devente J, Fessel J, et al.
Poster #LB-9 presented at: the Annual Meeting of the Infectious Diseases Society of America (IDSA); October 20-23, 2011; Boston, Massachusetts, USA.
Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
2011
J Virol.
Toma J, Weinheimer SP, Stawiski E, et al.
85(8):3872-3880.